Home › Funds › ACUTA CAPITAL PARTNERS, LLC › FDMT

ACUTA CAPITAL PARTNERS, LLC position in FDMT

4D MOLECULAR THERAPEUTICS IN · Health Care

ACUTA CAPITAL PARTNERS, LLC reported holding 507,801 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$6.8M, representing 4.71% of its reported portfolio and ranking #6 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed FDMT holdings in 3 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)507.80K sh
Reported value held$6.75M
Portfolio Weight4.71%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ACUTA CAPITAL PARTNERS, LLC's FDMT position evolved

ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in FDMT in Q4 2023 at 74,500 shares (US$1.5M). The position peaked in Q2 2026 at 507,801 shares, worth US$6.8M. Across 3 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 507,801 shares valued at US$6.8M — an increase of 265,546 shares quarter over quarter.. Notable position changes include a 110% increase in Q2 2026 (shares rose 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 74.50K $1.51M New
Q1 2026 242.25K $2.26M New
Q2 2026 507.80K $6.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FDMT and 13F data

FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FDMT

All FDMT fund holders →

FAQ

How long has ACUTA CAPITAL PARTNERS, LLC held FDMT?

ACUTA CAPITAL PARTNERS, LLC has disclosed FDMT holdings in 3 of the last 11 reported quarters, going back to Q4 2023.

What is ACUTA CAPITAL PARTNERS, LLC's current position in FDMT?

As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 507.80K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $6.75M, representing 4.71% of its reported portfolio and ranking #6.

Has ACUTA CAPITAL PARTNERS, LLC been buying or selling FDMT?

In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in FDMT. The position peaked in Q2 2026 at 507.80K shares.

Which other funds hold FDMT?

Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.